GRIFOLS
Highly Engaged Employees
Highly Engaged EmployeesBlood & Organ Banks · Spain · 10K+ Employees
View Company Info for Free
Overview
Headquarters
Avinguda De La Generalitat Sant Cugat De...Phone Number
+34 935712200Website
www.grifols.comRevenue
$7 BillionStock Symbol
GRFIndustry
ZI Rank: 28
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
29
20
26
46
31
28
About GRIFOLS
Grifols is becoming increasingly global. A diverse team will remain a key component to our future success. Do you want to know more about one of the leading healthcare companies? Here you will find all the information about Grifols and our commitment to improving the health and well-being of people around world. We are a global healthcare company founded in Barcelona, Spain. Since 1940, we have been committed to improving the health and well-being of people around the world. We are an industry leader in producing plasma-derived medicines for patients around the world. Our business is organized into four divisions: Bioscience, Diagnostic, Hospital and Bio Supplies. We sell our products and services in more than 100 countries and have subsidiaries in 30. We aim to be a global leader in our markets and an industry reference for quality, safety and innovation. Grifols' history of growth demonstrates its capacity to evolve and make a positive impact on society. We take great pride in our etRead more
GRIFOLS Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is GRIFOLS your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on GRIFOLS recently announced quarterly report
GRIFOLS, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if GRIFOLS is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at GRIFOLS
Funding: Get notified immidiatlly once GRIFOLS has new funding data
Click to see if GRIFOLS had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check if GRIFOLS has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when GRIFOLS launches new products
Recommended Actions
Reach out to Masked Content who joined GRIFOLS as Masked Content
Find 3 more new buyers
Compare Similar Companies to GRIFOLS
Compare insights from companies similar to GRIFOLS, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
GRIFOLS
$7B
10K+
Public
-
2019
MR
Marilyn Rosa-BrayChief Medical Officer & Global Senior VP, Plasma Quality & Regulatory Affairs
$11.3B
10K+
Public
-
1931
Stacey EisenSenior Vice President, Chief Communications Officer and Corporate Marketing, and President, Baxter Foundation
Company Profile Activity
Activity Insights
GRIFOLS is experiencing low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
GRIFOLS is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about GRIFOLS.
GRIFOLS Tech Stack
A closer look at the technologies used by GRIFOLS
See more technologies
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Open Position
Open Position
Project
Laboratory Operations, Medical Research, Clinical Operations
Hiring Plans
Hiring Plans
GRIFOLS News & Media
Grifols, S.A. (GIKLY) Q2 2026 Earnings Call Transcript
Grifols, S.A. (GIKLY) Q2 2026 Earnings Call July 28, 2026 12:30 PM EDTCompany ParticipantsDaniel Segarra - Head of Investor Relations & Sustainability...Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins
BARCELONA, Spain, July 16, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced that the first patients have been dosed in two separate Phase 3 trials aiming to expand the U.S. labels for its signature immunoglobulin therapeutics, GAMUNEX®-C, an intravenous immunoglobulin (IVIg), and XEMBIFY®, its subcutaneous immunoglobulin (SCIg).REPEAT - Grifols deaths and harm: Patient safety & options for accountability
Patient safety issues related to Grifols, one of the world's largest manufacturers of plasma-derived medical products.Grifols deaths and harm: Patient safety & options for accountability
Patient safety issues related to Grifols, one of the world's largest manufacturers of plasma-derived medical products.
Read more news
Top Blood & Organ Banks Companies
See more top companies
Frequently Asked Questions Regarding GRIFOLS
Sign Up For FreeTo access detailed company insights
Grifols is becoming increasingly global. A diverse team will remain a key component to our future success. Do you want to know more about one of the leading healthcare companies? Here you will find all the information about Grifols and our commitment to improving the health and well-being of people around world. We are a global healthcare company f... Read More
